top of page
Texture transparente

Les publications les plus récentes

Lacombe, V., Beucher, A., Urbanski, G., Le Corre, Y., Cottin, L., Croué, A., Bouvier, A., 2022. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 11, 6. https://doi.org/10.1186/s40164-022-00262-5

Desprez, C., Riou, J., Peterlin, P., Marchand, T., Couturier, M.-A., Villate, A., Mear, J.-B., Chevalier, P., Guillerm, G., Gyan, E., Schmidt-Tanguy, A., Walter, R.B., Hunault-Berger, M., Orvain, C., 2022. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study. Leukemia 36, 2408–2417. https://doi.org/10.1038/s41375-022-01677-z

Lemoine, S., Mornet, C., Quintin-Roue, I., Rousselet, M.-C., Cottin, L., Georgeais, A., Dubouis, L., Boyer, F., Orvain, C., Caillon, C., Renard, M., Le Brun, V., Le Clech, L., Ianotto, J.-C., Génin, E., Burroni, B., Ugo, V., Paz, D.L., Lippert, E., 2022. Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis. haematol 107, 2725–2731. https://doi.org/10.3324/haematol.2022.280917

Roux, B., Picou, F., Debeissat, C., Koubi, M., Gallay, N., Hirsch, P., Ravalet, N., Béné, M.C., Maigre, M., Hunault, M., Mosser, J., Etcheverry, A., Gyan, E., Delhommeau, F., Domenech, J., Herault, O., 2022. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Ther 29, 1263–1275. https://doi.org/10.1038/s41417-022-00441-w

PRODUCTION SCIENTIFIQUE

2022

____________________________________________2020 _____________________________________________

 

Baccini, V., Geneviève, F., Jacqmin, H., Chatelain, B., Girard, S., Wuilleme, S., Vedrenne, A., Guiheneuf, E., Toussaint-Hacquard, M., Everaere, F., Soulard, M., Lesesve, J.-F., Bardet, V., 2020. Platelet Counting: Ugly Traps and Good Advice. Proposals from the French-Speaking Cellular Hematology Group (GFHC). JCM 9, 808. https://doi.org/10.3390/jcm9030808

Bouvier, A., Riou, J., Thépot, S., Sutra Del Galy, A., François, S., Schmidt, A., Orvain, C., Estienne, M.-H., Villate, A., Luque Paz, D., Cottin, L., Ribourtout, B., Beucher, A., Delneste, Y., Ifrah, N., Ugo, V., Hunault-Berger, M., Blanchet, O., 2020. Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation. Leukemia 34, 1342–1353. https://doi.org/10.1038/s41375-019-0624-4

Cottin, L., Riou, J., Orvain, C., Ianotto, J.C., Boyer, F., Renard, M., Truchan‐Graczyk, M., Murati, A., Jouanneau‐Courville, R., Allangba, O., Mansier, O., Burroni, B., Rousselet, M.-C., Quintin‐Roué, I., Martin, A., Sadot‐Lebouvier, S., Delneste, Y., Chrétien, J., Hunault‐Berger, M., Blanchet, O., Lippert, E., Ugo, V., Luque Paz, D., 2020. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol 188, 935–944. https://doi.org/10.1111/bjh.16276

El-Khoury, M., Cabagnols, X., Mosca, M., Vertenoeil, G., Marzac, C., Favale, F., Bluteau, O., Lorre, F., Tisserand, A., Rabadan Moraes, G., Ugo, V., Ianotto, J.-C., Rey, J., Solary, E., Roy, L., Rameau, P., Debili, N., Pasquier, F., Casadevall, N., Marty, C., Constantinescu, S.N., Raslova, H., Vainchenker, W., Plo, I., 2020. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene 39, 5323–5337. https://doi.org/10.1038/s41388-020-1368-3

Feriel, J., Depasse, F., Geneviève, F., 2020. How I investigate basophilia in daily practice. Int J Lab Hem 42, 237–245. https://doi.org/10.1111/ijlh.13146

Kouzi, F., Zibara, K., Bourgeais, J., Picou, F., Gallay, N., Brossaud, J., Dakik, H., Roux, B., Hamard, S., Le Nail, L.-R., Hleihel, R., Foucault, A., Ravalet, N., Rouleux-Bonnin, F., Gouilleux, F., Mazurier, F., Bene, M.C., Akl, H., Gyan, E., Domenech, J., El-Sabban, M., Herault, O., 2020. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. Oncogene 39, 1198–1212. https://doi.org/10.1038/s41388-019-1069-y

Paillassa, J., Cornet, E., Noel, S., Tomowiak, C., Lepretre, S., Vaudaux, S., Dupuis, J., Devidas, A., Joly, B., Petitdidier-Lionnet, C., Haiat, S., Mariette, C., Thieblemont, C., Decaudin, D., Validire-Charpy, P., Drenou, B., Eisenmann, J.-C., Uribe, M.O., Olivrie, A., Touati, M., Lambotte, O., Hermine, O., Karsenti, J.-M., Feugier, P., Vaillant, W., Gutnecht, J., Lippert, E., Huysman, F., Ghomari, K., Boubaya, M., Levy, V., Riou, J., Damaj, G., Tanguy-Schmidt, A., Hunault-Berger, M., Troussard, X., 2020. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 10, 62. https://doi.org/10.1038/s41408-020-0328-z

Luque Paz, D., Jouanneau-Courville, R., Riou, J., Ianotto, J.-C., Boyer, F., Chauveau, A., Renard, M., Chomel, J.-C., Cayssials, E., Gallego-Hernanz, M.-P., Pastoret, C., Murati, A., Courtier, F., Rousselet, M.-C., Quintin-Roué, I., Cottin, L., Orvain, C., Thépot, S., Chrétien, J.-M., Delneste, Y., Ifrah, N., Blanchet, O., Hunault-Berger, M., Lippert, E., Ugo, V., 2020. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Advances 4, 4887–4897. https://doi.org/10.1182/bloodadvances.2020002271

Orvain, C., Balsat, M., Tavernier, E., Marolleau, J.-P., Pabst, T., Chevallier, P., de Gunzburg, N., Cacheux, V., Rigal-Huguet, F., Chantepie, S., Caillot, D., Chalandon, Y., Frayfer, J., Bonmati, C., Lheritier, V., Ifrah, N., Dombret, H., Boissel, N., Hunault-Berger, M., 2020. Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study. Blood blood.2020004919. https://doi.org/10.1182/blood.2020004919

Vantyghem, S., Peterlin, P., Thépot, S., Ménard, A., Dubruille, V., Debord, C., Guillaume, T., Garnier, A., Le Bourgeois, A., Wuilleme, S., Godon, C., Theisen, O., Eveillard, M., Delaunay, J., Maisonneuve, H., Morineau, N., Villemagne, B., Vigouroux, S., Subiger, F., Lestang, E., Loirat, M., Parcelier, A., Godmer, P., Mercier, M., Trebouet, A., Luque Paz, D., Le Calloch, R., Le Clech, L., Bossard, C., Moreau, A., Ugo, V., Hunault, M., Moreau, P., Le Gouill, S., Chevallier, P., Béné, M.C., Le Bris, Y., 2020. Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica haematol.2019.242677. https://doi.org/10.3324/haematol.2019.242677

____________________________________________2019 _____________________________________________

Beucher, A., Dib, M., Orvain, C., Bouvier, A., Jouanneau‐Courville, R., Dobo, I., Cottin, L., Guardiola, P., Rousselet, M., Blanchet, O., Hunault, M., Ugo, V., Luque Paz, D., 2019. Next generation sequencing redefines a triple negative essential thrombocythaemia as double‐positive with rare mutations on JAK 2 V617 and MPL W515 hotspots. Br J Haematol 186, 785–788. https://doi.org/10.1111/bjh.15954

 

Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., Perrier, P., Alsafadi, S., Wassef, M., Margueron, R., Rousseau, A., Droin, N., Cagnard, N., Kaltenbach, S., Winter, S., Kubasch, A.-S., Bouscary, D., Santini, V., Toma, A., Hunault, M., Stamatoullas, A., Gyan, E., Cluzeau, T., Platzbecker, U., Adès, L., Puy, H., Stern, M.-H., Karim, Z., Mayeux, P., Nemeth, E., Park, S., Ganz, T., Kautz, L., Kosmider, O., Fontenay, M., 2019. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med 11. https://doi.org/10.1126/scitranslmed.aav5467

Cottin, L., Riou, J., Boyer, F., Bouvier, A., Zannetti, A., Blouet, A., Truchan-Graczyk, M., Jouanneau-Courville, R., Beucher, A., Ribourtout, B., Orvain, C., Hunault-Berger, M., Blanchet, O., Ugo, V., Luque Paz, D., 2019. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood Cells, Molecules, and Diseases 75, 35–40. https://doi.org/10.1016/j.bcmd.2018.12.004

Guénot, C., Lacombe, F., Allou, K., Dumezy, F., Feuillard, J., Geneviève, F., Guérin, E., Guy, J., Maynadié, M., Ballon, O.W., Preudhomme, C., Baruchel, A., Dombret, H., Ifrah, N., Béné, M.C., Groupe d’Etude Immunologique des Leucémies (GEIL), 2019. Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia 33, 1814–1816. https://doi.org/10.1038/s41375-019-0393-0

Leveque, X., Hochane, M., Geraldo, F., Dumont, S., Gratas, C., Oliver, L., Gaignier, C., Trichet, V., Layrolle, P., Heymann, D., Herault, O., Vallette, F.M., Olivier, C., 2019. Low-Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro. Stem Cells 37, 1083–1094. https://doi.org/10.1002/stem.3014

Luque Paz, D., Mansier, O., Riou, J., Conejero, C., Roy, L., Belkhodja, C., Ugo, V., Giraudier, S., 2019. Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience. Haematologica 104, e134–e137. https://doi.org/10.3324/haematol.2018.197699

Mheidly, K., Lamy De La Chapelle, T., Hunault, M., Benboubker, L., Benchalal, M., Moreau, P., Baugier de Materre, A., Decaux, O., Laribi, K., 2019. New insights in the treatment of patients with solitary bone plasmacytoma. Leuk Lymphoma 60, 2810–2813. https://doi.org/10.1080/10428194.2019.1605067

Picou, F., Vignon, C., Debeissat, C., Lachot, S., Kosmider, O., Gallay, N., Foucault, A., Estienne, M.-H., Ravalet, N., Bene, M.C., Domenech, J., Gyan, E., Fontenay, M., Herault, O., 2019. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv 3, 4271–4279. https://doi.org/10.1182/bloodadvances.2019000677

Sébert, M., Renneville, A., Bally, C., Peterlin, P., Beyne-Rauzy, O., Legros, L., Gourin, M.-P., Sanhes, L., Wattel, E., Gyan, E., Park, S., Stamatoullas, A., Banos, A., Laribi, K., Jueliger, S., Bevan, L., Chermat, F., Sapena, R., Nibourel, O., Chaffaut, C., Chevret, S., Preudhomme, C., Adès, L., Fenaux, P., 2019. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica 104, 1565–1571. https://doi.org/10.3324/haematol.2018.207118

Tanasi, I., Ba, I., Sirvent, N., Braun, T., Cuccuini, W., Ballerini, P., Duployez, N., Tanguy-Schmidt, A., Tamburini, J., Maury, S., Doré, E., Himberlin, C., Duclos, C., Chevallier, P., Rousselot, P., Bonifacio, M., Cavé, H., Baruchel, A., Dombret, H., Soulier, J., Landman-Parker, J., Boissel, N., Clappier, E., 2019. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood 134, 1351–1355. https://doi.org/10.1182/blood.2019001244

____________________________________________2018 _____________________________________________

Blouet, A., Rousselet, M.-C., Le Bris, Y., Ribourtout, B., Bouvier, A., Cottin, L., Jouanneau-Courville, R., Blanchet, O., Ugo, V., Luque Paz, D., 2018. Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia: HemaSphere 2, e29. https://doi.org/10.1097/HS9.0000000000000029

Bouvier, A., Ribourtout, B., François, S., Orvain, C., Luque Paz, D., Beucher, A., Guérard, A., Guardiola, P., Ugo, V., Blanchet, O., Geneviève, F., Schmidt, A., Hunault-Berger, M., 2018. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 101, 570–574. https://doi.org/10.1111/ejh.13143

Dumas, P.-Y., Mansier, O., Prouzet-Mauleon, V., Koya, J., Villacreces, A., Brunet de la Grange, P., Luque Paz, D., Bidet, A., Pasquet, J.-M., Praloran, V., Salin, F., Kurokawa, M., Mahon, F.-X., Cardinaud, B., Lippert, E., 2018. MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms. BMC Cancer 18, 1098. https://doi.org/10.1186/s12885-018-4993-2

Garban, F., Guyard, A., Labussière, H., Bulabois, C.-E., Marchand, T., Mounier, C., Caillot, D., Bay, J.-O., Coiteux, V., Schmidt-Tanguy, A., Le Niger, C., Robin, C., Ladaique, P., Lapusan, S., Deconinck, E., Rolland, C., Foote, A.M., François, A., Jacquot, C., Tardivel, R., Tiberghien, P., Bosson, J.-L., Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group, 2018. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. JAMA Oncol 4, 468–475. https://doi.org/10.1001/jamaoncol.2017.5123

Gillet, N., Fouquereau, E., Coillot, H., Bonnetain, F., Dupont, S., Moret, L., Anota, A., Colombat, P., 2018. Ethical leadership, professional caregivers’ well-being, and patients’ perceptions of quality of care in oncology. Eur J Oncol Nurs 33, 1–7. https://doi.org/10.1016/j.ejon.2018.01.002

Girerd, S., Tosca, L., Herault, O., Vignon, C., Biard, D., Aggoune, D., Dkhissi, F., Bonnet, M.L., Sorel, N., Desterke, C., Bennaceur-Griscelli, A., Tachdjian, G., Guilhot, F., Guilhot, J., Chomel, J.-C., Turhan, A.G., 2018. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. Biochem Biophys Res Commun 498, 715–722. https://doi.org/10.1016/j.bbrc.2018.03.023

Huguet, F., Chevret, S., Leguay, T., Thomas, X., Boissel, N., Escoffre-Barbe, M., Chevallier, P., Hunault, M., Vey, N., Bonmati, C., Lepretre, S., Marolleau, J.-P., Pabst, T., Rousselot, P., Buzyn, A., Cahn, J.-Y., Lhéritier, V., Béné, M.C., Asnafi, V., Delabesse, E., Macintyre, E., Chalandon, Y., Ifrah, N., Dombret, H., for the Group of Research on Adult ALL (GRAALL), 2018. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. J Clin Oncol 36, 2514–2523. https://doi.org/10.1200/JCO.2017.76.8192

Ianotto, J.-C., Chauveau, A., Boyer-Perrard, F., Gyan, E., Laribi, K., Cony-Makhoul, P., Demory, J.-L., de Renzis, B., Dosquet, C., Rey, J., Roy, L., Dupriez, B., Knoops, L., Legros, L., Malou, M., Hutin, P., Ranta, D., Benbrahim, O., Ugo, V., Lippert, E., Kiladjian, J.-J., 2018. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 103, 438–446. https://doi.org/10.3324/haematol.2017.181297

Lacombe, F., Campos, L., Allou, K., Arnoulet, C., Delabarthe, A., Dumezy, F., Feuillard, J., Geneviève, F., Guérin, E., Guy, J., Jouault, H., Lepelley, P., Maynadié, M., Solly, F., Ballon, O.W., Preudhomme, C., Baruchel, A., Dombret, H., Ifrah, N., Béné, M.C., on behalf of the Groupe d’Etude Immunologique des Leucémies (GEIL), 2018. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol 36, 422–428. https://doi.org/10.1002/hon.2488

Le Bourgeois, A., Labopin, M., Leclerc, M., de Latour, R.P., Bourhis, J.-H., Ceballos, P., Orvain, C., Wallet, H.L., Bilger, K., Blaise, D., Rubio, M.-T., Guillaume, T., Mohty, M., Chevallier, P., Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, 2018. Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Oncotarget 9, 36603–36612. https://doi.org/10.18632/oncotarget.26391

Le Calloch, R., Lacut, K., Le Gall-Ianotto, C., Nowak, E., Abiven, M., Tempescul, A., Dalbies, F., Eveillard, J.-R., Ugo, V., Giraudier, S., Guillerm, G., Lippert, E., Berthou, C., Ianotto, J.-C., 2018. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study). Haematologica 103, 607–613. https://doi.org/10.3324/haematol.2017.180448

Luque Paz, D., Boyer, F., Beucher, A., Bouvier, A., Jouanneau-Courville, R., Guardiola, P., Lambert, D., Delneste, Y., Hunault, M., Blanchet, O., Ugo, V., 2018. Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis. Blood Cells Mol Dis 71, 75–76. https://doi.org/10.1016/j.bcmd.2018.04.002

Mansier, O., Luque Paz, D., Ianotto, J.-C., Le Bris, Y., Chauveau, A., Boyer, F., Conejero, C., Fitoussi, O., Riou, J., Adiko, D., Touati, M., Chauzeix, J., Viallard, J.-F., Béné, M.C., Giraudier, S., Ugo, V., Lippert, E., 2018. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 93, E84–E86. https://doi.org/10.1002/ajh.25014

Mollard, L.-M., Chauveau, A., Boyer-Perrard, F., Douet-Guilbert, N., Houot, R., Quintin-Roué, I., Couturier, M.-A., Dagorne, A., Malou, M., Le Calloch, R., Luycx, O., Thepot, S., Hunault, M., Guillerm, G., Berthou, C., Ugo, V., Lippert, É., Ianotto, J.-C., 2018. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leuk Lymphoma 59, 2812–2820. https://doi.org/10.1080/10428194.2018.1441408

Paillassa, J., Leguay, T., Thomas, X., Huguet, F., Audrain, M., Lheritier, V., Vianey-Saban, C., Acquaviva-Bourdain, C., Pagan, C., Dombret, H., Ifrah, N., Boissel, N., Hunault-Berger, M., 2018. Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial. Blood Cancer J 8, 45. https://doi.org/10.1038/s41408-018-0084-5

Pigneux, A., Béné, M.C., Salmi, L.-R., Dumas, P.-Y., Delaunay, J., Bonmati, C., Guièze, R., Luquet, I., Cornillet-Lefebvre, P., Delabesse, E., Ianotto, J.-C., Ojeda-Uribe, M., Hunault, M., Banos, A., Fornecker, L.M., Bernard, M., Jourdan, E., Vey, N., Zerazhi, H., Hishri, Y., Mineur, A., Asselineau, J., Delepine, R., Cahn, J.-Y., Ifrah, N., Récher, C., on behalf of the French Innovative Leukemia Organization, 2018. Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. J Clin Oncol 36, 3203–3210. https://doi.org/10.1200/JCO.2018.78.7366

Poiré, X., Labopin, M., Polge, E., Passweg, J., Craddock, C., Blaise, D., Cornelissen, J.J., Volin, L., Russell, N.H., Socié, G., Michallet, M., Fegueux, N., Chevallier, P., Brecht, A., Hunault-Berger, M., Mohty, M., Esteve, J., Nagler, A., 2018. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 103, 256–265. https://doi.org/10.3324/haematol.2017.178251

____________________________________________2017 _____________________________________________

Alloin, A.-L., Leverger, G., Dalle, J.-H., Galambrun, C., Bertrand, Y., Baruchel, A., Auvrignon, A., Gandemer, V., Ragu, C., Loundou, A., Bilhou-Nabera, C., Lafage-Pochitaloff, M., Dastugue, N., Nelken, B., Jubert, C., Rialland, F., Plat, G., Pochon, C., Vannier, J.-P., Rohrlich, P.-S., Kanold, J., Lutz, P., Sirvent, A., Oudin, C., Cuccuini, W., Michel, G., on behalf of the ELAM study group, 2017. Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience. Bone Marrow Transplant 52, 516–521. https://doi.org/10.1038/bmt.2016.293

Bergeron, A., Chevret, S., Granata, A., Chevallier, P., Vincent, L., Huynh, A., Tabrizi, R., Labussiere-Wallet, H., Bernard, M., Chantepie, S., Bay, J.-O., Thiebaut-Bertrand, A., Thepot, S., Contentin, N., Fornecker, L.-M., Maillard, N., Risso, K., Berceanu, A., Blaise, D., Peffault de La Tour, R., Chien, J.W., Coiteux, V., Socié, G., ALLOZITHRO Study Investigators, 2017. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA 318, 557–566. https://doi.org/10.1001/jama.2017.9938

Cahu, X., Carré, M., Recher, C., Pigneux, A., Hunault-Berger, M., Vey, N., Chevallier, P., Delaunay, J., Gyan, E., Lioure, B., Bonmati, C., Himberlin, C., Hicheri, Y., Guillerm, G., Didier, B., Larosa, F., Ojeda-Uribe, M., Bernard, M., Bene, M.C., Ifrah, N., Cahn, J.-Y., 2017. Impact of body-surface area on patients’ outcome in younger adults with acute myeloid leukemia. Eur J Haematol 98, 443–449. https://doi.org/10.1111/ejh.12850

Chauveau, A., Nibourel, O., Tondeur, S., Luque Paz, D., Mansier, O., Paul, F., Wemeau, M., Preudhomme, C., Lippert, E., Ugo, V., 2017. Absence of CALR mutations in JAK2 -negative polycythemia. Haematologica 102, e15–e16. https://doi.org/10.3324/haematol.2016.154799

Chevalier, S., Lejeune, J., Fouquereau, E., Coillot, H., Gillet, N., Gandemer, V., Michon, J., Colombat, P., 2017. Organizational and Managerial Resources and Quality of Care in French Pediatric Oncology Nursing. J Pediatr Oncol Nurs 34, 406–413. https://doi.org/10.1177/1043454217717238

Chevallier, P., Chantepie, S., Huguet, F., Raffoux, E., Thomas, X., Leguay, T., Marchand, T., Isnard, F., Charbonnier, A., Maury, S., Gallego-Hernanz, M.-P., Robillard, N., Guillaume, T., Peterlin, P., Garnier, A., Rialland, F., Le Houerou, C., Goldenberg, D.M., Wegener, W.A., Béné, M.-C., Dombret, H., 2017. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. Haematologica 102, e184–e186. https://doi.org/10.3324/haematol.2016.159905

Chretien, A.-S., Devillier, R., Fauriat, C., Orlanducci, F., Harbi, S., Le Roy, A., Rey, J., Bouvier Borg, G., Gautherot, E., Hamel, J.-F., Ifrah, N., Lacombe, C., Cornillet-Lefebvre, P., Delaunay, J., Toubert, A., Arnoulet, C., Vey, N., Blaise, D., Olive, D., 2017a. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. Oncoimmunology 6, e1307491. https://doi.org/10.1080/2162402X.2017.1307491

Chretien, A.-S., Fauriat, C., Orlanducci, F., Galseran, C., Rey, J., Bouvier Borg, G., Gautherot, E., Granjeaud, S., Hamel-Broza, J.-F., Demerle, C., Ifrah, N., Lacombe, C., Cornillet-Lefebvre, P., Delaunay, J., Toubert, A., Gregori, E., Luche, H., Malissen, M., Arnoulet, C., Nunes, J.A., Vey, N., Olive, D., 2017b. Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. Front. Immunol. 8, 573. https://doi.org/10.3389/fimmu.2017.00573

Desbourdes, L., Javary, J., Charbonnier, T., Ishac, N., Bourgeais, J., Iltis, A., Chomel, J.-C., Turhan, A., Guilloton, F., Tarte, K., Demattei, M.-V., Ducrocq, E., Rouleux-Bonnin, F., Gyan, E., Hérault, O., Domenech, J., 2017. Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis. Stem Cells Dev 26, 709–722. https://doi.org/10.1089/scd.2016.0295

Douet-Guilbert, N., Chauveau, A., Gueganic, N., Guillerm, G., Tous, C., Le Bris, M.-J., Basinko, A., Morel, F., Ugo, V., De Braekeleer, M., 2017. Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion: Cryptic ins(16) in AML. Hematol Oncol 35, 385–389. https://doi.org/10.1002/hon.2268

Fausser, J.-L., Tavenard, A., Rialland, F., Le Moine, P., Minckes, O., Jourdain, A., Tirel, O., Pellier, I., Gandemer, V., 2017. Should We Pay Attention to the Delay Before Admission to a Pediatric Intensive Care Unit for Children With Cancer? Impact on 1-Month Mortality. A Report From the French Children’s Oncology Study Group, GOCE: J Pediatr Hematol Onco 39, e244–e248. https://doi.org/10.1097/MPH.0000000000000816

Hunault-Berger, M., Maillard, N., Himberlin, C., Recher, C., Schmidt-Tanguy, A., Choufi, B., Bonmati, C., Carré, M., Couturier, M.-A., Daguindau, E., Marolleau, J.-P., Orsini-Piocelle, F., Delaunay, J., Tavernier, E., Lissandre, S., Ojeda-Uribe, M., Sanhes, L., Sutton, L., Banos, A., Fornecker, L.M., Bernard, M., Bouscary, D., Saad, A., Puyade, M., Rouillé, V., Luquet, I., Béné, M.C., Hamel, J.-F., Dreyfus, F., Ifrah, N., Pigneux, A., for the FILO Group, 2017. Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial. Blood Cancer J. 7, e568–e568. https://doi.org/10.1038/bcj.2017.50

Ianotto, J.-C., Chauveau, A., Mottier, D., Ugo, V., Berthou, C., Lippert, E., Delluc, A., 2017. JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort. Ann Hematol 96, 383–386. https://doi.org/10.1007/s00277-016-2853-1

Lafage-Pochitaloff, M., Baranger, L., Hunault, M., Cuccuini, W., Lefebvre, C., Bidet, A., Tigaud, I., Eclache, V., Delabesse, E., Bilhou-Nabéra, C., Terré, C., Chapiro, E., Gachard, N., Mozziconacci, M.-J., Ameye, G., Porter, S., Grardel, N., Béné, M.C., Chalandon, Y., Graux, C., Huguet, F., Lhéritier, V., Ifrah, N., Dombret, H., 2017. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood 130, 1832–1844. https://doi.org/10.1182/blood-2017-05-783852

Le Gall‐Ianotto, C., Brenaut, E., Gouillou, M., Lacut, K., Nowak, E., Tempescul, A., Berthou, C., Ugo, V., Carré, J.L., Misery, L., Ianotto, J.C., 2017. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol 176, 255–258. https://doi.org/10.1111/bjd.14809

Luque Paz, D., Chauveau, A., Boyer, F., Buors, C., Samaison, L., Cottin, L., Seegers, V., Férec, C., Le Maréchal, C., Gueguen, P., Lippert, E., Ianotto, J.-C., Ugo, V., 2017. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome: Mutations associated with disease outcome in PV and ET. Genes Chromosomes Cancer 56, 354–362. https://doi.org/10.1002/gcc.22437

Pastoret, C., Houot, R., Llamas-Gutierrez, F., Boulland, M.-L., Marchand, T., Tas, P., Ly-Sunnaram, B., Gandemer, V., Lamy, T., Roussel, M., Fest, T., 2017. Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing. Leuk Lymphoma 58, 1008–1012. https://doi.org/10.1080/10428194.2016.1225208

Pigneux, A., Béné, M.C., Guardiola, P., Recher, C., Hamel, J.-F., Sauvezie, M., Harousseau, J.-L., Tournilhac, O., Witz, F., Berthou, C., Escoffre-Barbe, M., Guyotat, D., Fegueux, N., Himberlin, C., Hunault, M., Delain, M., Lioure, B., Jourdan, E., Bauduer, F., Dreyfus, F., Cahn, J.-Y., Sotto, J.-J., Ifrah, N., 2017. Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. J Clin Oncol 35, 387–393. https://doi.org/10.1200/JCO.2016.67.6213

____________________________________________2016 _____________________________________________

Bond, J., Marchand, T., Touzart, A., Cieslak, A., Trinquand, A., Sutton, L., Radford-Weiss, I., Lhermitte, L., Spicuglia, S., Dombret, H., Macintyre, E., Ifrah, N., Hamel, J.-F., Asnafi, V., 2016. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica 101, 732–740. https://doi.org/10.3324/haematol.2015.141218

Brissot, E., Rialland, F., Cahu, X., Strullu, M., Corradini, N., Thomas, C., Blin, N., Rialland, X., Thebaud, E., Chevallier, P., Moreau, P., Milpied, N., Harousseau, J.L., Mechinaud, F., Mohty, M., 2016. Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. Bone Marrow Transplant 51, 267–272. https://doi.org/10.1038/bmt.2015.250

Cabagnols, X., Favale, F., Pasquier, F., Messaoudi, K., Defour, J.P., Ianotto, J.C., Marzac, C., Le Couédic, J.P., Droin, N., Chachoua, I., Favier, R., Diop, M.K., Ugo, V., Casadevall, N., Debili, N., Raslova, H., Bellanné-Chantelot, C., Constantinescu, S.N., Bluteau, O., Plo, I., Vainchenker, W., 2016. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 127, 333–342. https://doi.org/10.1182/blood-2015-07-661983

Chauveau, A., Luque Paz, D., Lecucq, L., Le Gac, G., Le Maréchal, C., Gueguen, P., Berthou, C., Ugo, V., 2016. A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis. Br J Haematol 172, 475–477. https://doi.org/10.1111/bjh.13511

Chevallier, P., Labopin, M., La Tour, R.P., Lioure, B., Bulabois, C., Huynh, A., Blaise, D., Turlure, P., Daguindau, E., Maillard, N., Yakoub‐Agha, I., Guillerm, G., Delage, J., Contentin, N., Bay, J., Beckerich, F., Bourhis, J., Detrait, M., Vigouroux, S., François, S., Legrand, F., Guillaume, T., Mohty, M., the SFGM‐TC, 2016. Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. Cancer Med 5, 3068–3076. https://doi.org/10.1002/cam4.880

Desjonquères, A., Chevallier, P., Thomas, X., Huguet, F., Leguay, T., Bernard, M., Bay, J.-O., Tavernier, E., Charbonnier, A., Isnard, F., Hunault, M., Turlure, P., Renaud, M., Bastié, J.-N., Himberlin, C., Lepretre, S., Lioure, B., Lhéritier, V., Asnafi, V., Beldjord, K., Lafage-Pochitaloff, M., Béné, M.C., Ifrah, N., Dombret, H., on behalf of the French Group for Research in Adult ALL (GRAALL), 2016. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J 6, e504–e504. https://doi.org/10.1038/bcj.2016.111

Desjonqueres, A., Illiaquer, M., Duquesne, A., Le Bris, Y., Peterlin, P., Guillaume, T., Delaunay, J., Rialland, F., Moreau, P., Béné, M.C., Chevallier, P., Eveillard, M., 2016. Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation. Bone Marrow Transplant 51, 1150–1152. https://doi.org/10.1038/bmt.2016.80

Gillet, B., Ianotto, J.-C., Mingant, F., Didier, R., Gilard, M., Ugo, V., Lippert, E., Galinat, H., 2016. Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. Thromb Res 142, 26–32. https://doi.org/10.1016/j.thromres.2016.04.006

Grain, A., Sirvent, A., Strullu, M., Françoise, M., Mohty, M., Guillaume, T., Chevallier, P., Rialland, F., 2016. Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). Leuk Lymphoma 57, 2937–2941. https://doi.org/10.1080/10428194.2016.1177721

Guièze, R., Damaj, G., Pereira, B., Robin, M., Chevallier, P., Michallet, M., Vigouroux, S., Beguin, Y., Blaise, D., El Cheikh, J., Roos-Weil, D., Thiebaut, A., Rohrlich, P.-S., Huynh, A., Cornillon, J., Contentin, N., Suarez, F., Lioure, B., Mohty, M., Maillard, N., Clement, L., François, S., Guillerm, G., Yakoub-Agha, I., 2016. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biol Blood Marrow Transplant 22, 240–247. https://doi.org/10.1016/j.bbmt.2015.07.037

Haro, S., Tavenard, A., Rialland, F., Taque, S., Guillerm, G., Blouin, P., Esvan, M., Pellier, I., Gandemer, V., 2016. Keep in Mind Quality of Life: Outcome of a Ten-Year Series of Post-Transplantation Early Relapses in Childhood Acute Lymphoblastic Leukemia—A Report from the Grand Ouest Oncology Study Group for Children in France. Biol Blood Marrow Transplant 22, 889–894. https://doi.org/10.1016/j.bbmt.2016.01.025

Ianotto, J.-C., Chauveau, A., Luque Paz, D., Delluc, A., Tromeur, C., Couturier, M.-A., Gouillou, M., Berthou, C., Mottier, D., Ugo, V., 2016. Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. Thromb Haemost 115, 225–226. https://doi.org/10.1160/TH15-02-0134

Jaspers, A., Bouhya, S., Belaiche, S., Chevallier, P., Hermet, E., Hospital-Gustems, C., Michallet, M., Rialland, F., Samsonova, O., Sirvent, A., Yakoub-Agha, I., Rohrlich, P.-S., Beguin, Y., 2016. Évaluation et prise en charge de la surcharge en fer post-greffe : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 103, S255–S266. https://doi.org/10.1016/j.bulcan.2016.09.003

Lepretre, S., Touzart, A., Vermeulin, T., Picquenot, J.-M., Tanguy-Schmidt, A., Salles, G., Lamy, T., Béné, M.-C., Raffoux, E., Huguet, F., Chevallier, P., Bologna, S., Bouabdallah, R., Benichou, J., Brière, J., Moreau, A., Tallon-Simon, V., Seris, S., Graux, C., Asnafi, V., Ifrah, N., Macintyre, E., Dombret, H., 2016. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol 34, 572–580. https://doi.org/10.1200/JCO.2015.61.5385

Luque Paz, D., Ianotto, J.-C., Chauveau, A., Guibourg, B., Lecucq, L., Lippert, E., Ugo, V., 2016. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib. Ann Hematol 95, 349–350. https://doi.org/10.1007/s00277-015-2518-5

Mahé, K., Luque Paz, D., Couturier, M.-A., Chauveau, A., Quintin-Roué, I., Berthou, C., Ugo, V., Lippert, E., Ianotto, J.-C., 2016. Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients. Ann Hematol 95, 529–531. https://doi.org/10.1007/s00277-015-2559-9

Malard, F., Labopin, M., Chevallier, P., Guillaume, T., Duquesne, A., Rialland, F., Derenne, S., Peterlin, P., Leauté, A.-G., Brissot, E., Gregoire, M., Moreau, P., Saas, P., Gaugler, B., Mohty, M., 2016. Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. Blood 127, 1828–1835. https://doi.org/10.1182/blood-2015-12-688739

Maury, S., Chevret, S., Thomas, X., Heim, D., Leguay, T., Huguet, F., Chevallier, P., Hunault, M., Boissel, N., Escoffre-Barbe, M., Hess, U., Vey, N., Pignon, J.-M., Braun, T., Marolleau, J.-P., Cahn, J.-Y., Chalandon, Y., Lhéritier, V., Beldjord, K., Béné, M.C., Ifrah, N., Dombret, H., for GRAALL, 2016. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med 375, 1044–1053. https://doi.org/10.1056/NEJMoa1605085

Michel, G., Galambrun, C., Sirvent, A., Pochon, C., Bruno, B., Jubert, C., Loundou, A., Yakoub-Agha, I., Milpied, N., Lutz, P., Marie-Cardine, A., Gandemer, V., Blaise, D., Michallet, M., Rialland, F., Renard, C., Oudin, C., Esmiol, S., Seux, M., Baumstarck, K., Mohty, M., Rocha, V., Dalle, J.-H., 2016. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood 127, 3450–3457. https://doi.org/10.1182/blood-2016-01-694349

Nelken, B., Cave, H., Leverger, G., Galambrun, C., Plat, G., Schmitt, C., Thomas, C., Vérité, C., Brethon, B., Gandemer, V., Bertrand, Y., Baruchel, A., Rohrlich, P., 2016. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). Pediatr Blood Cancer 63, 270–275. https://doi.org/10.1002/pbc.25751

Orvain, C., Luque Paz, D., Dobo, I., Cottin, L., Le Calvez, G., Chauveau, A., Mercier, M., Farhi, J., Boyer, F., Ianotto, J.C., Guibourg, B., Rousselet, M.C., Zandecki, M., Ifrah, N., Hunault-Berger, M., Ugo, V., Genevieve, F., 2016. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Ann Hematol 95, 1819–1823. https://doi.org/10.1007/s00277-016-2784-x

Ravinet, A., Cabrespine, A., Socié, G., Milpied, N., Yakoub Agha, I., Nguyen, S., Michallet, M., Menard, A.L., Maillard, N., Mohty, M., Suarez, F., Huynh, A., Marchand, T., Deteix, C., Cassuto, J.P., Maury, S., Chevallier, P., Reman, O., Peffault de Latour, R., Bay, J.O., 2016. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Transplantation 100, 1732–1739. https://doi.org/10.1097/TP.0000000000000976

Rousselot, P., Coudé, M.M., Gokbuget, N., Gambacorti Passerini, C., Hayette, S., Cayuela, J.-M., Huguet, F., Leguay, T., Chevallier, P., Salanoubat, C., Bonmati, C., Alexis, M., Hunault, M., Glaisner, S., Agape, P., Berthou, C., Jourdan, E., Fernandes, J., Sutton, L., Banos, A., Reman, O., Lioure, B., Thomas, X., Ifrah, N., Lafage-Pochitaloff, M., Bornand, A., Morisset, L., Robin, V., Pfeifer, H., Delannoy, A., Ribera, J., Bassan, R., Delord, M., Hoelzer, D., Dombret, H., Ottmann, O.G., 2016. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL. Blood 128, 774–782. https://doi.org/10.1182/blood-2016-02-700153

Visentin, S., Auquier, P., Bertrand, Y., Baruchel, A., Tabone, M.-D., Pochon, C., Jubert, C., Poirée, M., Gandemer, V., Sirvent, A., Bonneau, J., Paillard, C., Freycon, C., Kanold, J., Villes, V., Berbis, J., Oudin, C., Galambrun, C., Pellier, I., Plat, G., Chambost, H., Leverger, G., Dalle, J.-H., Michel, G., 2016. The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucémie de l’Enfant et de L’Adolescent Study. Biol Blood Marrow Transplant 22, 2003–2010. https://doi.org/10.1016/j.bbmt.2016.08.004

____________________________________________2015 _____________________________________________

Boissel, N., Renneville, A., Leguay, T., Lefebvre, P.C., Recher, C., Lecerf, T., Delabesse, E., Berthon, C., Blanchet, O., Prebet, T., Pautas, C., Chevallier, P., Leprêtre, S., Girault, S., Bonmati, C., Guièze, R., Himberlin, C., Randriamalala, E., Preudhomme, C., Jourdan, E., Dombret, H., Ifrah, N., 2015. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 100, 780–785. https://doi.org/10.3324/haematol.2014.114884

Cabagnols, X., Defour, J.P., Ugo, V., Ianotto, J.C., Mossuz, P., Mondet, J., Girodon, F., Alexandre, J.H., Mansier, O., Viallard, J.F., Lippert, E., Murati, A., Mozziconacci, M.J., Saussoy, P., Vekemans, M.C., Knoops, L., Pasquier, F., Ribrag, V., Solary, E., Plo, I., Constantinescu, S.N., Casadevall, N., Vainchenker, W., Marzac, C., Bluteau, O., 2015. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 29, 249–252. https://doi.org/10.1038/leu.2014.270

Chalandon, Y., Thomas, X., Hayette, S., Cayuela, J.-M., Abbal, C., Huguet, F., Raffoux, E., Leguay, T., Rousselot, P., Lepretre, S., Escoffre-Barbe, M., Maury, S., Berthon, C., Tavernier, E., Lambert, J.-F., Lafage-Pochitaloff, M., Lhéritier, V., Chevret, S., Ifrah, N., Dombret, H., 2015. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125, 3711–3719. https://doi.org/10.1182/blood-2015-02-627935

Chevallier, P., Eugene, T., Robillard, N., Isnard, F., Nicolini, F., Escoffre-Barbe, M., Huguet, F., Hunault, M., Marcais, A., Gaschet, J., Cherel, M., Guillaume, T., Delaunay, J., Peterlin, P., Eveillard, M., Thomas, X., Ifrah, N., Lapusan, S., Bodet-Milin, C., Barbet, J., Faivre-Chauvet, A., Ferrer, L., Bene, M.C., Le Houerou, C., Goldenberg, D.M., Wegener, W.A., Kraeber-Bodéré, F., 2015a. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol 2, e108-117. https://doi.org/10.1016/S2352-3026(15)00020-4

Chevallier, P., Labopin, M., Socie, G., Rubio, M.-T., Blaise, D., Vigouroux, S., Huynh, A., Michallet, M., Bay, J.-O., Maury, S., Yakoub-Agha, I., Fegueux, N., Deconinck, E., Contentin, N., Maillard, N., Bulabois, C.-E., Francois, S., Oumedaly, R., Raus, N., Mohty, M., 2015b. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Eur J Haematol 94, 449–455. https://doi.org/10.1111/ejh.12451

Chien, W.W., Catallo, R., Chebel, A., Baranger, L., Thomas, X., Béné, M.-C., Gerland, L.M., Schmidt, A., Beldjord, K., Klein, N., Escoffre-Barbe, M., Leguay, T., Huguet, F., Larosa, F., Hayette, S., Plesa, A., Ifrah, N., Dombret, H., Salles, G., Chassevent, A., Ffrench, M., 2015. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. Leuk Res 39, 453–461. https://doi.org/10.1016/j.leukres.2015.01.008

Couturier, M.-A., Huguet, F., Chevallier, P., Suarez, F., Thomas, X., Escoffre-Barbe, M., Cacheux, V., Pignon, J.-M., Bonmati, C., Sanhes, L., Bories, P., Daguindau, E., Dorvaux, V., Reman, O., Frayfer, J., Orvain, C., Lhéritier, V., Ifrah, N., Dombret, H., Hunault-Berger, M., Tanguy-Schmidt, A., 2015. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l -asparaginase: The GRAALL experience: Incidence, Risk Factors, and Management of CNS Thrombosis. Am. J. Hematol. 90, 986–991. https://doi.org/10.1002/ajh.24130

Dhédin, N., Huynh, A., Maury, S., Tabrizi, R., Beldjord, K., Asnafi, V., Thomas, X., Chevallier, P., Nguyen, S., Coiteux, V., Bourhis, J.-H., Hichri, Y., Escoffre-Barbe, M., Reman, O., Graux, C., Chalandon, Y., Blaise, D., Schanz, U., Lhéritier, V., Cahn, J.-Y., Dombret, H., Ifrah, N., 2015. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood 125, 2486–2496. https://doi.org/10.1182/blood-2014-09-599894

Fossat, C., Roussel, M., Arnoux, I., Asnafi, V., Brouzes, C., Garnache-Ottou, F., Jacob, M.C., Kuhlein, E., Macintyre-Davi, E., Plesa, A., Robillard, N., Tkaczuk, J., Ifrah, N., Dombret, H., Béné, M.C., Baruchel, A., Garand, R., for the French Multicenter Study Groups for Pediatric and Adult ALL, 2014. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study: Cytometry. Part B, Clinical Cytometry 8821-29. https://doi.org/10.1002/cytob.21195

Huet, S., Dulucq, S., Chauveau, A., Ménard, A., Chomel, J.-C., Maisonneuve, H., Legros, L., Perrin, M.-C., Ferrant, E., Moreilhon, C., Couturier, M.-A., Sujobert, P., Magaud, J.-P., Ugo, V., Chabane, K., Raynaud, S., Hayette, S., GBMHM (Groupe des Biologistes Moléculaires des Hémopathies Malignes, French Molecular Biology Group in Hematology), 2015. Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts: Characterization of five new BCR-ABL1 transcripts. Genes Chromosomes Cancer 54, 595–605. https://doi.org/10.1002/gcc.22263

Hunault-Berger, M., Leguay, T., Huguet, F., Leprêtre, S., Deconinck, E., Ojeda-Uribe, M., Bonmati, C., Escoffre-Barbe, M., Bories, P., Himberlin, C., Chevallier, P., Rousselot, P., Reman, O., Boulland, M.-L., Lissandre, S., Turlure, P., Bouscary, D., Sanhes, L., Legrand, O., Lafage-Pochitaloff, M., Béné, M.C., Liens, D., Godfrin, Y., Ifrah, N., Dombret, H., Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), 2015. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study: L-asparaginase within erythrocytes in elderly ALL patients. Am. J. Hematol. 90, 811–818. https://doi.org/10.1002/ajh.24093

Itzykson, R., Thépot, S., Berthon, C., Delaunay, J., Bouscary, D., Cluzeau, T., Turlure, P., Prébet, T., Dartigeas, C., Marolleau, J.-P., Recher, C., Plantier, I., Stamatoullas, A., Devidas, A., Taksin, A.-L., Guièze, R., Caillot, D., Vey, N., Adès, L., Ifrah, N., Dombret, H., Fenaux, P., Gardin, C., 2015. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res 39, 124–130. https://doi.org/10.1016/j.leukres.2014.11.009

Verger, E., Cassinat, B., Chauveau, A., Dosquet, C., Giraudier, S., Schlageter, M.-H., Ianotto, J.-C., Yassin, M.A., Al-Dewik, N., Carillo, S., Legouffe, E., Ugo, V., Chomienne, C., Kiladjian, J.-J., 2015. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 126, 2585–2591. https://doi.org/10.1182/blood-2015-07-659060

2021
2020
2019

____________________________________________2021 _____________________________________________

Baroud, M., Lepeltier, E., Thepot, S., El-Makhour, Y., Duval, O., 2021. The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery. Nanoscale Adv. 3, 2157–2179. https://doi.org/10.1039/D0NA01084G

Couturier, M.-A., Thomas, X., Raffoux, E., Huguet, F., Berthon, C., Simand, C., Gallego-Hernanz, M.-P., Hicheri, Y., Hunault Berger, M., Saillard, C., Leguay, T., Loiseau, C., Béné, M.-C., Chevallier, P., 2021. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma 62, 620–629. https://doi.org/10.1080/10428194.2020.1844198

 

Foucault, A., Vallet, N., Ravalet, N., Picou, F., Bene, M.C., Gyan, E., Herault, O., 2021. Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of case–control studies including 3,955 cases and 9,948 controls. Sci Rep 11, 2007. https://doi.org/10.1038/s41598-021-81604-x

Foucault, A., Ravalet, N., Besombes, J., Picou, F., Gallay, N., Babin, L., Bourgeais, J., Hamard, S., Domenech, J., Loyer, P., Vallet, N., Lejeune, J., Gyan, E., Béné, M.C., Vallette, F., Olivier, C., Hérault, O., 2021. Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition. Cancers 13, 5699. https://doi.org/10.3390/cancers13225699

Lacombe, V., Prevost, M., Bouvier, A., Thépot, S., Chabrun, F., Kosmider, O., Lacout, C., Beucher, A., Lavigne, C., Geneviève, F., Urbanski, G., 2021. Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold. Br J Haematol 195, 286–289. https://doi.org/10.1111/bjh.17679

Lacombe, V., Nunes Gomes, C., Robin, J., Thépot, S., François, S., Cottin, L., Ugo, V., Dieu, X., Abgueguen, P., Daniel, V., Giltat, A., Hunault, M., Riou, J., Orvain, C., Schmidt, A., 2021. Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations. Eur J Haematol 107, 489–496. https://doi.org/10.1111/ejh.13686

Lemoine, S., Renard, M., Bouvier, A., Orvain, C., Giltat, A., Cottin, L., Blanchet, O., Hunault-Berger, M., Ugo, V., Luque Paz, D., 2021. No detection of atypical one-base deletion of CALR exon 9 with fragment analysis: A molecular trap to avoid. Blood Cells, Molecules, and Diseases 90, 102589. https://doi.org/10.1016/j.bcmd.2021.102589

Luque Paz, D., Cottin, L., Lippert, E., Robin, J.-B., Bescond, C., Genevieve, F., Boyer, F., Quintin-Roue, I., Rousselet, M.-C., Burroni, B., Hunault-Berger, M., Ugo, V., Ianotto, J.-C., Orvain, C., 2021. Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis. Ann Hematol. https://doi.org/10.1007/s00277-021-04672-z

Peterlin, P., Gaschet, J., Guillaume, T., Garnier, A., Eveillard, M., Le Bourgeois, A., Cherel, M., Debord, C., Le Bris, Y., Theisen, O., Godon, C., Mahé, B., Dubruille, V., Wuilleme, S., Touzeau, C., Gastinne, T., Blin, N., Lok, A., Tessoulin, B., Le Gouill, S., Moreau, P., Béné, M.-C., Chevallier, P., 2021. A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. Cancer Med 10, 642–648. https://doi.org/10.1002/cam4.3648

 

Ravalet, N., Foucault, A., Picou, F., Gombert, M., Renoult, E., Lejeune, J., Vallet, N., Lachot, S., Rault, E., Gyan, E., Bene, M.C., Herault, O., 2021. Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckman-Coulter DxH 800 Hematology Analyzer. Cancers (Basel) 13. https://doi.org/10.3390/cancers13030389

Sureau, L., Orvain, C., Ianotto, J.-C., Ugo, V., Kiladjian, J.-J., Luque Paz, D., Riou, J., 2021. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. Blood Cancer J. 11, 135. https://doi.org/10.1038/s41408-021-00526-z

Tondeur, S., Paul, F., Riou, J., Mansier, O., Ranta, D., Le Clech, L., Lippert, E., Tavitian, S., Chaoui, D., Mercier, M., De Renzis, B., Cottin, L., Cassinat, B., Chrétien, J.-M., Ianotto, J.-C., Allangba, O., Marzac, C., Voillat, L., Boyer, F., Orvain, C., Hunault-Berger, M., Girodon, F., Kiladjian, J.-J., Ugo, V., Luque Paz, D., 2021. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia 35, 871–875. https://doi.org/10.1038/s41375-020-0991-x

2018

____________________________________________2022 _____________________________________________

 

Desprez, C., Riou, J., Peterlin, P., Marchand, T., Couturier, M.-A., Villate, A., Mear, J.-B., Chevalier, P., Guillerm, G., Gyan, E., Schmidt-Tanguy, A., Walter, R.B., Hunault-Berger, M., Orvain, C., 2022. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study. Leukemia 36, 2408–2417. https://doi.org/10.1038/s41375-022-01677-z

Drevin, G., Briet, M., Bazzoli, C., Gyan, E., Schmidt, A., Dombret, H., Orvain, C., Giltat, A., Recher, C., Ifrah, N., Guardiola, P., Hunault-Berger, M., Abbara, C., 2022. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics 14, 792. https://doi.org/10.3390/pharmaceutics14040792

Dulucq, S., Nicolini, F.E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., Guerci-Bresler, A., Legros, L., Ianotto, J.-C., Gardembas, M., Turlure, P., Dubruille, V., Rousselot, P., Martiniuc, J., Jardel, H., Johnson-Ansah, H., Joly, B., Henni, T., Cayssials, E., Zunic, P., Berger, M.G., Villemagne, B., Robbesyn, F., Morisset, S., Mahon, F.-X., Etienne, G., 2022. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. haematol 107, 2859–2869. https://doi.org/10.3324/haematol.2022.280811

Gyan, E., Pigneux, A., Hunault, M., Peterlin, P., Carré, M., Bay, J.-O., Bonmati, C., Gallego-Hernanz, M.-P., Lioure, B., Bertrand, P., Vallet, N., Ternant, D., Darrouzain, F., Picou, F., Béné, M.-C., Récher, C., Hérault, O., 2022. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. Sci Rep 12, 9748. https://doi.org/10.1038/s41598-022-13626-y

Lacombe, V., Beucher, A., Urbanski, G., Le Corre, Y., Cottin, L., Croué, A., Bouvier, A., 2022. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 11, 6. https://doi.org/10.1186/s40164-022-00262-5

Lemoine, S., Mornet, C., Quintin-Roue, I., Rousselet, M.-C., Cottin, L., Georgeais, A., Dubouis, L., Boyer, F., Orvain, C., Caillon, C., Renard, M., Le Brun, V., Le Clech, L., Ianotto, J.-C., Génin, E., Burroni, B., Ugo, V., Paz, D.L., Lippert, E., 2022. Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis. haematol 107, 2725–2731. https://doi.org/10.3324/haematol.2022.280917

Passet, M., Kim, R., Gachet, S., Sigaux, F., Chaumeil, J., Galland, A., Sexton, T., Quentin, S., Hernandez, L., Larcher, L., Bergugnat, H., Ye, T., Karasu, N., Caye, A., Heizmann, B., Duluc, I., Chevallier, P., Rousselot, P., Huguet, F., Leguay, T., Hunault, M., Pflumio, F., Freund, J.-N., Lobry, C., Lhéritier, V., Dombret, H., Domon-Dell, C., Soulier, J., Boissel, N., Clappier, E., 2022. Concurrent CDX2 cis -deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Blood 139, 3505–3518. https://doi.org/10.1182/blood.2021014723

Roux, B., Picou, F., Debeissat, C., Koubi, M., Gallay, N., Hirsch, P., Ravalet, N., Béné, M.C., Maigre, M., Hunault, M., Mosser, J., Etcheverry, A., Gyan, E., Delhommeau, F., Domenech, J., Herault, O., 2022. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Ther 29, 1263–1275. https://doi.org/10.1038/s41417-022-00441-w

Sureau, L., Buors, C., Ianotto, J.-C., Boyer, F., Tanguy-Schmidt, A., Roy, L., Cayssials, E., Cailly, L., Chomel, J.-C., Chauveau, A., Orvain, C., Mansier, O., Ranta, D., Robles, M., Gyan, E., Hérault, O., Nimubona, S., Marchand, T., Lippert, E., Riou, J., Ugo, V., Luque Paz, D., 2022. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes. Blood Cancer J. 12, 56. https://doi.org/10.1038/s41408-022-00646-0

2017
2016
2015
bottom of page